Results 161 to 170 of about 115,048 (305)
Acute Acalculous Cholecystitis Mimicry: Symptomatic Hepatic Infiltration From Chronic Lymphocytic Leukemia Presenting as Cholestatic Liver Injury. [PDF]
Alnounou A, Zou H, Boamah H.
europepmc +1 more source
Spatial heterogeneity limits the sensitivity of bone marrow biopsies, resulting in false‐negative findings. Circulating tumour cells (CTCs) provide a systemic, stratified monitoring approach, using flow cytometry for high tumour burden and EuroFlow or allele‐specific oligonucleotide PCR (ASO‐PCR) for minimal residual disease to enable early relapse ...
Chin‐Mu Hsu +3 more
wiley +1 more source
Hairy Cell Leukemia With Aberrant CD5 and CD23 Expression: A Case Report and a Brief Literature Review. [PDF]
Alameddine Z +4 more
europepmc +1 more source
High-Risk Chronic Lymphocytic Leukemia in a Young Adult Treated With Reduced-Dosage, Fixed-Duration Ibrutinib and Venetoclax. [PDF]
Gutierrez CLD +3 more
europepmc +1 more source
Leveraging paired germline and somatic analysis to improve the classification of DDX41 variants
Summary Constitutional pathogenic variants in DDX41 predispose to myelodysplasia and acute myeloid leukaemia. Acquisition of subsequent somatic hits in the second allele is frequent, with notable recurrent variants at key hotspots. Sequencing of Deoxyribonucleic acid from blood/marrow of 239 patients with suspected/confirmed haematological malignancies
Andrew George +13 more
wiley +1 more source
Lymphocyte count and risk of chronic lymphocytic leukemia. [PDF]
Pahnke S +6 more
europepmc +1 more source
Summary Front‐Line therapy in CLL: Assessment of Ibrutinib‐containing Regimens (FLAIR) demonstrated improved progression‐free survival for ibrutinib and rituximab (IR) compared with fludarabine, cyclophosphamide and rituximab (FCR) in previously untreated chronic lymphocytic leukaemia (CLL).
David J. Allsup +23 more
wiley +1 more source
Auer Rod-Like Inclusions in Chronic Lymphocytic Leukemia: A Case Report. [PDF]
Zhang T, Xie L.
europepmc +1 more source
Chemotherapy‐induced WNT ligand secretion by bone marrow (BM) stroma drives acute lymphoblastic leukaemia (ALL) chemoresistance. WNT pathway inhibition disrupts this cross‐talk and restores therapeutic response, highlighting WNT inhibitors as a promising strategy to prevent relapse in ALL.
Foteini Kalampalika +4 more
wiley +1 more source
Hematolymphoid neoplasms involving the breast: A single institution clinicopathologic study of 59 patients. [PDF]
Vickery J +8 more
europepmc +1 more source

